/ /

Richard A. Lewis, MD
Richard A. Lewis, MD may be reached by email: [email protected]
ROCK inhibitors show promise in glaucoma treatment
A novel class of drugs ‒ rho-kinase, or ROCK inhibitors ‒ appears to lower IOP by relaxing the trabecular meshwork.
Fixed-dose combination glaucoma drug provides easy, safe IOP control
Once-daily dosing of one drop of Roclatan (Aerie Pharmaceuticals, Inc.), containing a fixed-dose combination of latanoprost and a rho kinase inhibitor and norepinephrine transport inhibitor, was clinically and statistically superior to administration of its individual components for controlling IOP in open-angle glaucoma or ocular hypertension.
Canaloplasty: the next step in the glaucoma surgery evolution
Unlike trabeculectomy, canaloplasty is a non-penetrating procedure that reduces the chance of inducing cataract or causing anterior segment inflammation


View Results